This site is intended for Healthcare Professionals only.

Merck seeks first US regulator’s authorisation for Covid-19 tablet


Share post:

Pharmaceutical company Merck said today (October 11) it has applied for US emergency use authorisation for its tablet to treat mild-to-moderate patients of Covid19, putting it on course to become the first oral antiviral medication for the disease.

Its authorisation could help change clinical management of Covid19 as the pill can be taken at home. The treatment, molnupiravir, could halve the chances of death or being hospitalised for those most at risk of contracting severe Covid19, according to the drugmaker.

The interim efficacy data on the drug, which has been developed with Ridgeback Biotherapeutics, had heavily impacted the shares of Covid19 vaccine makers when it was released last week.

Existing drugs from Gilead Sciences Inc’s infused antiviral remdesivir and generic steroid dexamethasone are generally given only once a patient is hospitalized.

Monoclonal antibody drugs from Regeneron Pharmaceuticals Inc and Eli Lilly have so far seen only limited use due to the difficulty in administering them.

No significant efficacy

In India, however, two drugmakers had last week sought to end late-stage trials of their generic versions of molnupiravir to treat moderate Covid19, according to study documents.

A source with the Drug Controller General of India had said the pill has not shown “significant efficacy” against moderate cases, but was successful against mild cases.

Merck said its trials are based on U.S. Food and Drug Administration definitions, which for moderate Covid19 describe blood oxygen levels as no lower than 93 per cent whereas the trials in India define moderate as blood oxygen levels between 90 and 93 per cent.


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Europe Sees Surge in Generic Medicines Withdrawals; UK Faces Doubling of Drug Shortages

Generic medicines for cancer and mental health on the Union List of Critical Medicines are disappearing, study reveals...

NHS to support newly-trained pharmacists with new £1.5 million investment

The new initiative is set to create highly-skilled placement opportunities in community pharmacies, GP surgeries, and care homes...

Professor Mahendra Patel joins UK Pharmacy Professional Leadership Advisory Board

The nine independent expert members of the UK Pharmacy Professional Leadership Advisory Board announced   Professor Mahendra Patel OBE,...

Silent suffering: 12k NHS staff reluctant to share mental health and well-being struggles

Latest UNISON survey underscores mental health absence affecting over 30 per cent of NHS staff including paramedics, and...